A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Progressed Despite First-line Sorafenib Therapy (AVF4572).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Oct 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 03 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.